daxibotulinumtoxin type A

Phase 2Biologic

RRevance Therapeutics, Inc.

daxibotulinumtoxin type A is one of 23 biologic programs targeting Plantar Fasciitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plantar FasciitisActive, not recruiting

Plantar FasciitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

39 competitors in Plantar Fasciitis

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

1 2

Marcaine

Plasma

1 4

Xeomin

MMerz Therapeutics GmbH

Approved

1 5

Botox

RRevance Therapeutics, Inc.

Phase 3

1 6

Decadron

AAspen Global Incorporated

Phase 2

2 7

Methylprednisolon

SSisli Hamidiye Etfal Training and Research Hospital

Approved

1 8

Xiaflex

GGrupo Espanol de Tumores Neuroendocrinos

Phase 2

1 9

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 2

—10

Naropin

FFresenius Kabi Oncology Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Plantar Fasciitis1 trial

DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

Terminated·RRevance Therapeutics, Inc.·Phase 2·NCT02973269·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for daxibotulinumtoxin type A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — daxibotulinumtoxin type A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for daxibotulinumtoxin type A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Revance Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: RRevance Therapeutics, Inc.

daxibotulinumtoxin type A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Plantar Fasciitis1 trial

References

Drug Info

Quick Facts

Related News